Human medicines European public assessment report (EPAR): Epidyolex, cannabidiol, Date of authorisation: 19/09/2019, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): MabThera, rituximab, Date of authorisation: 02/06/1998, Revision: 65, Status: Authorised

Human medicines European public assessment report (EPAR): Instanyl, fentanyl, Date of authorisation: 20/07/2009, Revision: 41, Status: Authorised

Human medicines European public assessment report (EPAR): Epivir, lamivudine, Date of authorisation: 08/08/1996, Revision: 51, Status: Authorised

Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Date of authorisation: 08/01/2018, Revision: 27, Status: Authorised

Timetable: Post-authorisation measures (PAMs) assessed by PRAC - ATMP

Timetable: Post-authorisation measure (PAM) assessed by PRAC

Human medicines European public assessment report (EPAR): Rivastigmine 1 A Pharma, rivastigmine, Date of authorisation: 11/12/2009, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Rivastigmine Hexal, rivastigmine, Date of authorisation: 11/12/2009, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Rivastigmine Sandoz, rivastigmine, Date of authorisation: 10/12/2009, Revision: 20, Status: Authorised